Thank you both. A few points in your posts which are new to me and worthy of a great analysis. I would then have to sum up my decision as lack of liquidity on BFLs part and KSL having traded well below its book value (~ 75cents per share) which given its financial performance and market conditions for future performance seemed highly inappropriate.
- Forums
- ASX - By Stock
- KSL
- Ann: Results of 2023 AGM
Ann: Results of 2023 AGM, page-26
-
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KSL (ASX) to my watchlist
|
|||||
Last
95.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $274.4M |
Open | High | Low | Value | Volume |
95.5¢ | 95.5¢ | 94.5¢ | $346.7K | 365.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 47710 | 94.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
95.5¢ | 54359 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.950 |
4 | 45504 | 0.940 |
6 | 112474 | 0.930 |
1 | 3222 | 0.925 |
5 | 46468 | 0.920 |
Price($) | Vol. | No. |
---|---|---|
0.950 | 1 | 1 |
0.955 | 53153 | 2 |
0.960 | 14624 | 2 |
0.970 | 13950 | 3 |
0.980 | 125500 | 7 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
KSL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online